Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fidelity National Information Servcs Inc (FIS) vs Mesoblast Limited (MESO) Price & Performance

Fidelity National Information Servcs IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Fidelity National Information Servcs Inc vs Mesoblast Limited — how do they compare? Fidelity National Information Servcs Inc trades at $43.33 (market cap $21.92B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Fidelity National Information Servcs Inc is far larger — about 10.1× Mesoblast Limited's market cap, and Fidelity National Information Servcs Inc pays a 4.14% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

FISMESO
Market Cap
$21.92B$2.16B
Sector
TechnologyTechnology
52-Week High
$72.77$20.96
52-Week Low
$37.72$12.88
Enterprise Value
$42.43B$2.17B
Dividend Yield
4.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fidelity National Information Servcs Inc

FIS trades at $42.77, down slightly on the day, with a bearish technical signal. The company reported Q2 2026 earnings of $1.48 per share, beating estimates, driven by Banking Solutions growth. Recent news highlights the global expansion of its Digital One Commercial platform into the APAC region. Valuation metrics appear attractive with a P/E of 6.57 and a consensus price target of $50.20, though the company lowered its full-year Capital Markets outlook.

The outlook is mixed; strong fundamentals and analyst support suggest upside potential, but near-term price action is weak and execution risks in the Capital Markets segment pose a challenge. The stock offers value but requires monitoring of the revised guidance and competitive pressures in the fintech space.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Fidelity National Information Servcs Inc

Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.

Read more on FIS

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO